Pretransplant Psoas Muscle Cross-Sectional Area and Postkidney Transplant Outcomes.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 08 12 2021
revised: 13 04 2022
accepted: 02 05 2022
pubmed: 7 8 2022
medline: 9 11 2022
entrez: 6 8 2022
Statut: ppublish

Résumé

Sarcopenia is associated with adverse outcomes in end-stage kidney disease. We evaluated if pretransplant sarcopenia affects posttransplant outcomes in kidney transplant (KT) recipients. In this single-center retrospective study of adult patients with end-stage kidney disease, we analyzed the association between pre-KT psoas muscle cross-sectional area and critical posttransplant outcomes of decline in estimated glomerular filtration rate (eGFR), graft loss, rehospitalization, and mortality using Cox proportional hazard model adjusted for age, sex, and race. Pre-KT abdomen and pelvic computed tomography scans performed during evaluation for KT eligibility were available for 573 KT recipients. Of these, 465 KT recipients received kidney alone transplant, 71 received simultaneous liver kidney transplant (SLK), and 37 received simultaneous pancreas kidney transplant (SPK). Patients were 49 (SD, 13) years old, 16% Black, and 60% men. For kidney alone transplant recipients, a higher psoas muscle cross-sectional area was associated with a shorter length of hospitalization (β coefficient = -0.003; 95% CI, -0.005 to -0.0007). Conversely, pre-KT psoas muscle cross-sectional area did not predict decline in eGFR, graft loss, mortality, or early rehospitalization. For SLK recipients, psoas muscle cross-sectional area did not predict any of the priori outcomes. For SPK recipients, higher pretransplant psoas muscle cross-sectional area predicted a longer length of hospitalization (β coefficient = 0.03; 95% CI, 0.01-0.05). There was no association between psoas muscle cross-sectional area and other outcomes assessed. Pretransplant psoas muscle cross-sectional areas are not predictive of post-transplant decline in eGFR, graft loss, rehospitalization or mortality in kidney alone, SPK, or SLK transplants.

Sections du résumé

BACKGROUND BACKGROUND
Sarcopenia is associated with adverse outcomes in end-stage kidney disease. We evaluated if pretransplant sarcopenia affects posttransplant outcomes in kidney transplant (KT) recipients.
METHODS METHODS
In this single-center retrospective study of adult patients with end-stage kidney disease, we analyzed the association between pre-KT psoas muscle cross-sectional area and critical posttransplant outcomes of decline in estimated glomerular filtration rate (eGFR), graft loss, rehospitalization, and mortality using Cox proportional hazard model adjusted for age, sex, and race.
RESULTS RESULTS
Pre-KT abdomen and pelvic computed tomography scans performed during evaluation for KT eligibility were available for 573 KT recipients. Of these, 465 KT recipients received kidney alone transplant, 71 received simultaneous liver kidney transplant (SLK), and 37 received simultaneous pancreas kidney transplant (SPK). Patients were 49 (SD, 13) years old, 16% Black, and 60% men. For kidney alone transplant recipients, a higher psoas muscle cross-sectional area was associated with a shorter length of hospitalization (β coefficient = -0.003; 95% CI, -0.005 to -0.0007). Conversely, pre-KT psoas muscle cross-sectional area did not predict decline in eGFR, graft loss, mortality, or early rehospitalization. For SLK recipients, psoas muscle cross-sectional area did not predict any of the priori outcomes. For SPK recipients, higher pretransplant psoas muscle cross-sectional area predicted a longer length of hospitalization (β coefficient = 0.03; 95% CI, 0.01-0.05). There was no association between psoas muscle cross-sectional area and other outcomes assessed.
CONCLUSIONS CONCLUSIONS
Pretransplant psoas muscle cross-sectional areas are not predictive of post-transplant decline in eGFR, graft loss, rehospitalization or mortality in kidney alone, SPK, or SLK transplants.

Identifiants

pubmed: 35933230
pii: S0041-1345(22)00418-3
doi: 10.1016/j.transproceed.2022.05.035
pmc: PMC10506176
mid: NIHMS1831797
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1816-1821

Subventions

Organisme : NIA NIH HHS
ID : K23 AG055666
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

J Digit Imaging. 2016 Apr;29(2):206-15
pubmed: 26482912
J Ren Nutr. 2018 Nov;28(6):380-392
pubmed: 30348259
J Am Coll Surg. 2010 Aug;211(2):271-8
pubmed: 20670867
Sci Rep. 2020 Nov 19;10(1):20215
pubmed: 33214629
Transplant Direct. 2020 Sep 25;6(10):e610
pubmed: 33062843
JPEN J Parenter Enteral Nutr. 2016 Mar;40(3):308-18
pubmed: 26392166
Blood Purif. 2020;49(1-2):202-211
pubmed: 31851983
J Vasc Surg. 2018 Feb;67(2):460-467
pubmed: 28843791
Kidney Int. 1998 Mar;53(3):773-82
pubmed: 9507226
J Am Soc Nephrol. 2013 Feb;24(3):337-51
pubmed: 23264684
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):586-598
pubmed: 33949807
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2079-88
pubmed: 25392147
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
Liver Transpl. 2014 Jun;20(6):640-8
pubmed: 24678005
Am J Kidney Dis. 2013 Dec;62(6):1141-50
pubmed: 23859719
Nephrol Dial Transplant. 2006 Aug;21(8):2210-6
pubmed: 16504974
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
J Ren Nutr. 2016 Jul;26(4):258-64
pubmed: 26994780
J Ren Nutr. 2021 Jul;31(4):342-350
pubmed: 33257228
Am J Cardiol. 2017 Apr 15;119(8):1275-1280
pubmed: 28215411
Nephrol Dial Transplant. 2015 Oct;30(10):1718-25
pubmed: 25999376
Am J Nephrol. 2007;27(3):279-86
pubmed: 17440263
Nephrol Dial Transplant. 1999 Oct;14(10):2427-32
pubmed: 10528668
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101692
pubmed: 33848672
Nephrol Dial Transplant. 2005 May;20(5):945-51
pubmed: 15769826
Eur Radiol. 2002 Apr;12(4):920-7
pubmed: 11960249
Biomed Res Int. 2020 Mar 07;2020:1586707
pubmed: 32219127
Am J Transplant. 2014 Nov;14(11):2444-5
pubmed: 25155434

Auteurs

Taylor Norris (T)

Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.

Robert Montgomery (R)

Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas.

Diane Cibrik (D)

Division of Nephrology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.

Mark Reintjes (M)

Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas.

Shweta Chakraborty (S)

Department of Radiology, University of Kansas Medical Center, Kansas City, Kansas.

Shelby Fishback (S)

Department of Radiology, University of Kansas Medical Center, Kansas City, Kansas.

Aditi Gupta (A)

Division of Nephrology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas. Electronic address: agupta@kumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH